These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

142 related articles for article (PubMed ID: 32743869)

  • 1. Accidental hydroxyurea overdosage in a child with sickle cell anemia: An African experience.
    Nnebe-Agumadu U; Adebayo IA; Nnodu O; Adekile A
    Pediatr Blood Cancer; 2020 Oct; 67(10):e28632. PubMed ID: 32743869
    [No Abstract]   [Full Text] [Related]  

  • 2. Hydroxyurea treatment in children with sickle cell anemia in Central America and the Caribbean countries.
    Svarch E; Machín S; Nieves RM; Mancia de Reyes AG; Navarrete M; Rodríguez H
    Pediatr Blood Cancer; 2006 Jul; 47(1):111-2. PubMed ID: 16550531
    [No Abstract]   [Full Text] [Related]  

  • 3. Massive accidental overdose of hydroxyurea in a young child with sickle cell anemia.
    Miller ST; Rey K; He J; Flanagan J; Fish BJ; Rogers ZR; Wang WC; Ware RE;
    Pediatr Blood Cancer; 2012 Jul; 59(1):170-2. PubMed ID: 21744485
    [TBL] [Abstract][Full Text] [Related]  

  • 4. When should hydroxyurea be used for children with sickle cell disease?
    Mueller BU
    Pediatrics; 2008 Dec; 122(6):1365-6. PubMed ID: 19047256
    [No Abstract]   [Full Text] [Related]  

  • 5. Resolution of cerebral artery stenosis in a child with sickle cell anemia treated with hydroxyurea.
    Grace RF; Su H; Sena L; Poussaint TY; Heeney MM; Gutierrez A
    Am J Hematol; 2010 Feb; 85(2):135-7. PubMed ID: 20052745
    [No Abstract]   [Full Text] [Related]  

  • 6. Hydroxyurea in sickle cell disease.
    Burke SM
    MCN Am J Matern Child Nurs; 1996; 21(4):210. PubMed ID: 8754440
    [No Abstract]   [Full Text] [Related]  

  • 7. [From Hemoglobin SS to SF: interest of hydroxyurea in the management of sickle cell disease in two Congolese children and review of the literature].
    Nkashama GM; Wakamb GK; Mulangu AM; Nkashama GM; Kupa BK; Numbi OL
    Pan Afr Med J; 2015; 21():124. PubMed ID: 26327961
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Hydroxyurea for Children with Sickle Cell Anemia in Sub-Saharan Africa.
    Tshilolo L; Tomlinson G; Williams TN; Santos B; Olupot-Olupot P; Lane A; Aygun B; Stuber SE; Latham TS; McGann PT; Ware RE;
    N Engl J Med; 2019 Jan; 380(2):121-131. PubMed ID: 30501550
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Increasing hydroxyurea use in children with sickle cell disease at Kamuzu Central Hospital, Malawi.
    Mvalo T; Topazian H; Kamthunzi P; Chen J; Kambalame I; Mafunga P; Mumba N; Chiume-Chiphaliwali M; Paseli K; Key N; Gopal S; Hoffman I; Ataga K; Westmoreland K
    Blood Adv; 2018 Nov; 2(Suppl 1):30-32. PubMed ID: 30504195
    [No Abstract]   [Full Text] [Related]  

  • 10. Hydroxyurea for sickle cell disease: a systematic review for efficacy and toxicity in children.
    Strouse JJ; Lanzkron S; Beach MC; Haywood C; Park H; Witkop C; Wilson RF; Bass EB; Segal JB
    Pediatrics; 2008 Dec; 122(6):1332-42. PubMed ID: 19047254
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Expanding the role of hydroxyurea in children with sickle cell disease.
    Rogers ZR; Buchanan GR
    J Pediatr; 2004 Sep; 145(3):287-8. PubMed ID: 15343174
    [No Abstract]   [Full Text] [Related]  

  • 12. Hydroxyurea Dose Escalation for Sickle Cell Anemia in Sub-Saharan Africa.
    John CC; Opoka RO; Latham TS; Hume HA; Nabaggala C; Kasirye P; Ndugwa CM; Lane A; Ware RE
    N Engl J Med; 2020 Jun; 382(26):2524-2533. PubMed ID: 32579813
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Robust clinical and laboratory response to hydroxyurea using pharmacokinetically guided dosing for young children with sickle cell anemia.
    McGann PT; Niss O; Dong M; Marahatta A; Howard TA; Mizuno T; Lane A; Kalfa TA; Malik P; Quinn CT; Ware RE; Vinks AA
    Am J Hematol; 2019 Aug; 94(8):871-879. PubMed ID: 31106898
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Hydroxyurea for children with sickle cell disease.
    Heeney MM; Ware RE
    Pediatr Clin North Am; 2008 Apr; 55(2):483-501, x. PubMed ID: 18381097
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Opportunities for model-based precision dosing in the treatment of sickle cell anemia.
    Dong M; Mizuno T; Vinks AA
    Blood Cells Mol Dis; 2017 Sep; 67():143-147. PubMed ID: 28807656
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Rapid and automated quantitation of dense red blood cells: A robust biomarker of hydroxyurea treatment response.
    Sadaf A; Quinn CT; Korpik JB; Pfeiffer A; Reynaud M; Niss O; Malik P; Ware RE; Kalfa TA; McGann PT
    Blood Cells Mol Dis; 2021 Sep; 90():102576. PubMed ID: 34020272
    [No Abstract]   [Full Text] [Related]  

  • 17. Use of hydroxyurea in prevention of stroke in children with sickle cell disease.
    Lefèvre N; Dufour D; Gulbis B; Lê PQ; Heijmans C; Ferster A
    Blood; 2008 Jan; 111(2):963-4; author reply 964. PubMed ID: 18182580
    [No Abstract]   [Full Text] [Related]  

  • 18. The role of hydroxyurea in the management of sickle cell disease.
    Davies SC; Gilmore A
    Blood Rev; 2003 Jun; 17(2):99-109. PubMed ID: 12642122
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Hydroxyurea Use After Transitions of Care Among Young Adults With Sickle Cell Disease and Tennessee Medicaid Insurance.
    Mathias JG; Nolan VG; Klesges LM; Badawy SM; Cooper WO; Hankins JS; Smeltzer MP
    JAMA Netw Open; 2021 Oct; 4(10):e2128971. PubMed ID: 34643722
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Cost-effectiveness of hydroxyurea in sickle cell anemia. Investigators of the Multicenter Study of Hydroxyurea in Sickle Cell Anemia.
    Moore RD; Charache S; Terrin ML; Barton FB; Ballas SK
    Am J Hematol; 2000 May; 64(1):26-31. PubMed ID: 10815784
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.